The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including:
- Bristol Myers Squibb Co's (NYSE: BMS) blood thinner, Eliquis
- Eli Lilly And Co's (NYSE: LLY) diabetes treatment, Jardiance.
- Johnson & Johnson's (NYSE: JNJ) Xarelto (blood thinner), Stelara (psoriasis, arthritis, ulcerative colitis, Crohn's disease), Imbruvica (blood cancer).
- Merck & Co Inc's (NYSE: MRK) blood pressure drug, Januvia.
- AstraZeneca Plc's (NASDAQ: AZN) Farxiga (chronic kidney disease, heart failure, type 2 diabetes).
- Novartis AG's (NYSE: NVS) heart failure drug Entresto.
- Amgen Inc's (NASDAQ: AMGN) arthritis medicine Enbrel.
- Novo ...